Literature DB >> 2982510

Effect of nitrosoureas on calmodulin activity in vitro and in mouse intestine in vivo.

S D Harrison, D M Mann, R C Giles.   

Abstract

The effects of BCNU, CCNU, methyl-CCNU, streptozotocin, and chlorozotocin on calmodulin activity were studied in vitro and in vivo. Preincubation of BCNU, CCNU, and methyl-CCNU with calmodulin produced a concentration-dependent inhibition of in vitro calmodulin activity expressed as stimulation of cyclic nucleotide phosphodiesterase. Cyclohexylisocyanate produced a similar inhibition. Streptozotocin and chlorozotocin had no effect. Calmodulin inhibition by methyl-CCNU was dependent on the concentration of calcium in the preincubation mixture. Administration of methyl-CCNU or chlorozotocin IP to CF1 mice produced a dose-dependent inhibition of calmodulin activity in the small intestine. Methyl-CCNU produced a significant decrease in intestinal calmodulin activity as early as 1 h after treatment, an effect that persisted up to 52 h. Morphologic changes in the intestinal crypt epithelial cells were evident between 27 h and 5 days after treatment, but not earlier than 27 h. Renal and testicular calmodulin activity and morphology were unaffected. Although it was not possible to correlate the extent of calmodulin inhibition with severity of the intestinal lesions, the data suggested a relationship between reduced activity of calmodulin in a tissue and the ultimate appearance of lesions. This apparent interaction between an antitumor drug and calmodulin in vivo could have multiple implications for cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982510     DOI: 10.1007/bf00434354

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  Qualitative and quantitative toxicity of sublethal doses of methyl-CCNU in BDF1 mice.

Authors:  E P Denine; S D Harrison; J C Peckham
Journal:  Cancer Treat Rep       Date:  1977 May-Jun

2.  A simplified method for the quantitative assay of small amounts of protein in biologic material.

Authors:  G R Schacterle; R L Pollack
Journal:  Anal Biochem       Date:  1973-02       Impact factor: 3.365

Review 3.  Calmodulin.

Authors:  C B Klee; T H Crouch; P G Richman
Journal:  Annu Rev Biochem       Date:  1980       Impact factor: 23.643

4.  Assay of calmodulin by Ca2+-dependent phosphodiesterase.

Authors:  R W Wallace; E A Tallant; W Y Cheung
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

5.  Ca-calmodulin mediates the DNA-synthetic response of calcium-deprived liver cells to the tumor promoter TPA.

Authors:  A Jones; A L Boynton; J P MacManus; J F Whitfield
Journal:  Exp Cell Res       Date:  1982-03       Impact factor: 3.905

Review 6.  Interaction of drugs with calmodulin. Biochemical, pharmacological and clinical implications.

Authors:  B Weiss; W C Prozialeck; T L Wallace
Journal:  Biochem Pharmacol       Date:  1982-07-01       Impact factor: 5.858

7.  Calmodulin, activated cyclic nucleotide phosphodiesterase, microtubules, and vinca alkaloids.

Authors:  K Watanabe; W L West
Journal:  Fed Proc       Date:  1982-05

8.  Calmodulin and the cell cycle: involvement in regulation of cell-cycle progression.

Authors:  J G Chafouleas; W E Bolton; H Hidaka; A E Boyd; A R Means
Journal:  Cell       Date:  1982-01       Impact factor: 41.582

9.  Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine.

Authors:  R Ganapathi; D Grabowski
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

10.  Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

View more
  2 in total

1.  Protection against cisplatin nephrotoxicity by prochlorperazine.

Authors:  R A Kramer
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Protection by chlorpromazine against lethality and renal toxicity of cisplatin in mice.

Authors:  M Ishikawa; M Ozaki; Y Takayanagi; K Sasaki
Journal:  Experientia       Date:  1992-12-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.